CD33 and acute myeloid leukemia: We next established the anti-tumor properties of the 123b-33bcCAR against four primary patient leukemia samples, including two CD123+CD33+ AML and two CD123+ B-ALL samples (PT1:AML, PT2:B-ALL, PT3:AML, and PT4:B-ALL) (Fig. 3, Supplementary Fig. S4C).